DISCLOSURES: Dr. Giovannucci and Dr. Harlan are Writing Group co-chairs. Dr. Bergenstal has served on scientific advisory boards or as a consultant to Medtronic, Abbott, Bayer Diabetes Care, Eli Lilly, Intuity Medical, MannKind, Novo Nordisk, Roche, Sanofi-Aventis, and Valeritas; has received research support from Amylin, Bayer Diabetes Care, Eli Lilly, MannKind, Medtronic, the National Institutes of Health (NIH), Novo Nordisk, ResMed, and LifeScan; and is a joint stockholder in Merck. Dr. Habel has received research support from Takeda, Merck, Genetech (Roche), and Sanofi-Aventis. Dr. Pollak has received research support from Pfizer and serves as a consultant to Sanofi-Aventis and Novo Nordisk. Dr. Regensteiner has received research support from the NIH and the American Diabetes Association and has received honoraria from the University of Colorado at Denver. Dr.Yee has served on the advisory board of Novo Nordisk. No other potential conflict of interest relevant to this article was reported.
Article first published online: 17 JUN 2010
Copyright © 2010 American Cancer Society, Inc.
CA: A Cancer Journal for Clinicians
Volume 60, Issue 4, pages 207–221, July/August 2010
How to Cite
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G. and Yee, D. (2010), Diabetes and Cancer: A Consensus Report. CA: A Cancer Journal for Clinicians, 60: 207–221. doi: 10.3322/caac.20078
The American Cancer Society and the American Diabetes Association thank the following companies for their unrestricted support of the consensus development conference: Amylin Pharmaceuticals, Inc; Lilly USA; Merck & Company, Inc; Novo Nordisk A/S; and the Sanofi-Aventis Groupe.
The authors thank the researchers who presented their work at the conference: Rachel Ballard-Barbash, MD, MPH; Frederick Brancati, MD, MHS; Peter T. Campbell, PhD; Edwin Gale, MD; Hertzel C. Gerstein, MD, MSc; Edward L. Giovannucci, MD, ScD; Pamela Goodwin, MD, MSc; Michael Goran, PhD; Jeffrey A. Johnson, PhD; Carol Koro, PhD; Larry Kushi, ScD; Derek Leroith, MD, PhD; Karin B. Michels, MPH, MS, MSc, PhD, ScD; Alpa V. Patel, PhD; Andrew Renehan, PhD; Ulf Smith, MD, PhD; Kevin Struhl, PhD; and Henry Thompson, PhD.
This article is jointly published by the American Diabetes Association and the American Cancer Society.
- Issue published online: 7 JUL 2010
- Article first published online: 17 JUN 2010
Epidemiologic evidence suggests that cancer incidence is associated with diabetes as well as certain diabetes risk factors and treatments. This consensus statement of experts assembled jointly by the American Diabetes Association and the American Cancer Society reviews the state of science concerning 1) the association between diabetes and cancer incidence or prognosis; 2) risk factors common to both diabetes and cancer; 3) possible biologic links between diabetes and cancer risk; and 4) whether diabetes treatments influence the risk of cancer or cancer prognosis. In addition, key unanswered questions for future research are posed. CA Cancer J Clin 2010. © 2010 American Cancer Society, Inc.